Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00370149
Other study ID # 0512-37
Secondary ID
Status Terminated
Phase Phase 4
First received August 28, 2006
Last updated January 27, 2016
Start date September 2006
Est. completion date May 2010

Study information

Verified date January 2016
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The primary purpose of the study is to determine if a therapeutic difference exists between central venous catheters impregnated with minocycline and rifampin and conventional catheters not impregnated with antibiotics when used in children at high risk for bloodstream infections (CABSI) after cardiac surgery.


Description:

The standard central venous catheter (CVC) is now commonly used for infants, children, and adults. The antibiotic-coated CVC is a newer CVC gaining popularity for use in adults. The Food and Drug Administration (FDA) and the Center for Disease Control (CDC) support use of the antibiotic-coated CVC for adult patients. But the FDA and CDC have not yet endorsed use of the antibiotic-coated CVC for infants and children due to lack of research on this CVC in infants and children.


Recruitment information / eligibility

Status Terminated
Enrollment 326
Est. completion date May 2010
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Both
Age group N/A to 17 Years
Eligibility Inclusion Criteria:

- Age < 18 years

- Cardiovascular surgery patient with a case complexity warranting CVC placement longer than 3 days

- Study devices of appropriate size for patient use without modification

- Informed consent obtained prior to patient entering the operating room

Exclusion Criteria:

- Age = 18 years

- Drug allergy to minocycline, other tetracyclines, or rifampin

- Ventricular assist device (VAD) therapy

- Extracorporeal membrane oxygenation (ECMO) therapy

- Patients undergoing cardiac transplant

- Any active infection or being treated for bacteremia at the time of randomization

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Device:
Antibiotic-impregnated Catheters (M/R)
Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
Non-impregnated Catheters (C/S)
Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.

Locations

Country Name City State
United States Riley Hospital for Children Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Indiana University School of Medicine

Country where clinical trial is conducted

United States, 

References & Publications (1)

Cox EG, Knoderer CA, Jennings A, Brown JW, Rodefeld MD, Walker SG, Turrentine MW. A Randomized, Controlled Trial of Catheter-Related Infectious Event Rates Using Antibiotic-Impregnated Catheters Versus Conventional Catheters in Pediatric Cardiovascular Su — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Catheter-related Bloodstream Infections (CRBSI) Per 1000 Catheter Days Rates of CRBSI defined as 1. micro-organism isolated from a blood culture; 2. Clinical manifestations of infection such as fever (=38 C) and/or hypotension (defined according to age-related practice guidelines for systolic blood pressure); 3. No apparent source for the bloodstream infection except for the catheter. Participants were followed for the duration of the hospital stay, an average of 6 days. No
Secondary Episodes of Clinical Sepsis and/or Infection With Identified Source Other Than Catheter A secondary outcome measure was episodes of clinical sepsis and/or infection with identified source other than the CVC. Participants were followed for the duration of hospital stay, an average of 6 days. No
Secondary Death Patient Death during hospitalization. Participants were followed for the duration of the hospital stay, an average of 6 days. No
See also
  Status Clinical Trial Phase
Terminated NCT03361085 - Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP) N/A
Completed NCT01810354 - PROPHYLACTIC ANTIBIOTICS PRIOR TO CESAREAN SECTION IN OBESE WOMEN N/A